Jiangsu Hengrui Pharmaceuticals (01276): R-Cotonib monotherapy for injection has been approved for new indications.
Hengrui Medicine (01276) announced that recently, its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received a notification from the National Medical Products Administration (NMPA) approving the addition of a new indication for the company's independently developed innovative drug, Rucannabidiol Monoclonal Antibody for Injection (SHR-A1811).
Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. received notification from the National Medical Products Administration (NMPA) approving the new indication for SHR-A1811, a type 1 innovative drug developed independently by the company, for injection.
Related Articles
ETS GROUP (08031): Xiao Wen'an appointed as the company's supervisor and authorized representative.
SOUNDWILL HOLD (00878) will distribute a final dividend of HK$0.1 per share on June 18th.
LITU HOLDINGS (01008) will distribute a final dividend of 2.6 Hong Kong cents per share on June 30th.
ETS GROUP (08031): Xiao Wen'an appointed as the company's supervisor and authorized representative.
SOUNDWILL HOLD (00878) will distribute a final dividend of HK$0.1 per share on June 18th.
LITU HOLDINGS (01008) will distribute a final dividend of 2.6 Hong Kong cents per share on June 30th.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
